The p16 (CDKN2a/INK4a) gene is an important tumor-suppressor gene, involved in the p16/cyclindependent kinase/retinoblastoma gene pathway of cell cycle control. The p16 protein is considered to be a negative regulator of the pathway. The gene encodes an inhibitor of cyclin-dependent kinases 4 and 6, which regulate the phosphorylation of retinoblastoma gene and the G1 to S phase transition of the cell cycle. In the present study, p16 gene promoter hypermethylation patterns and p16 protein expression were analyzed in 100 consecutive untreated cases of primary head and neck squamous cell carcinoma by methylation-specific PCR and immunohistochemical staining. The p16 promoter hypermethylation and apparent loss of p16 protein expression were detected in 27% and 74% of head and neck squamous cell carcinoma, respectively. By 2 test, history of alcohol or tobacco use was significantly correlated with the loss of p16 protein expression (P ‫؍‬ .005 and .05, respectively). When patient follow-up data were correlated with various clinical and molecular parameters, tumor size and nodal and clinical stage were the strongest prognostic predictors for disease-free survival (tumor recurrence) and for cause-specific and overall survival in patients with head and neck squamous cell carcinoma. Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression appears to be an independent prognostic factor, although loss of p16 protein may be used to predict overall patient survival in early-stage head and neck squamous cell carcinoma. 
The development of head and neck squamous cell carcinoma is believed to be a multistep process, in which genetic and epigenetic events accumulate as a result of chronic exposure to environmental carcinogens, resulting in loss of cell cycle control, selected cell growth, and finally the development of cancer.
On chromosome 9p21, the INK4a locus encodes both p16 and p14 ARF proteins by alternative splicing (1, 2) , in which exon 1␣ is used by p16 and exon 1␤ is used by p14 ARF . Although the role of p14 ARF as a true tumor suppressor has yet to be further characterized, p16 fulfills all the criteria for a bona fide tumor-suppressor gene, even judged with the strictest measures (3) . The human p16 protein contains 156 amino acids and was first discovered in a yeast two-hybrid system to detect proteins that interact with human cyclin-dependent kinase 4 (4) . The tumor suppressor function of p16 is attributed to its ability to inhibit the catalytic activity of the cyclin-dependent kinase 4 -6/cyclin D complex that is required for phosphorylation of retinoblastoma protein (5, 6) .
The E2F family of transcription factors is essential for cell cycle progression, and their transcriptional activity is inhibited through the specific binding to retinoblastoma protein b (7) . This retinoblastoma protein/E2F complex will release E2F transcriptional factors upon phosphorylation of ret-inoblastoma protein by cyclin dependent kinase 4 -6/cyclin D complex and promote cell cycle progression past the G 1 /S checkpoint (3, 7) . By binding to cyclin-dependent kinases 4 and 6 and inhibiting retinoblastoma protein phosphorylation, p16 prevents the formation of cyclin-dependent kinases 4 -6/cyclin D stimulatory complex and promotes the formation of retinoblastoma protein/E2F repressive complex, with the end result of blockage of cell cycle progression at the G 1 /S checkpoint (3) .
In head and neck squamous cell carcinoma, a number of studies have identified three major mechanisms by which p16 gene is inactivated, and these are homozygous deletions, inactivating mutation, and aberrant promoter methylation. In the review by Rocco and Sidransky (3) , the p16 inactivation was seen in Յ68% of primary human tumors and was caused by homozygous deletions in 27%, by inactivating mutations in 11%, and by promoter hypermethylation in 30% of the cases respectively.
It has been established that loss of p16 function occurs early in cancer progression (8, 9) , and some studies even indicate that p16 loss is the earliest detectable genetic abnormality in head and neck squamous cell carcinoma (10, 11) .
Consistent with the results of genetic and epigenetic analyses in head and neck squamous cell carcinoma, the p16 gene expression is frequently lost at the protein levels. The frequency of absent p16 protein expression by immunohistochemical staining method in head and neck squamous cell carcinoma ranges from 55 to 90% in three studies involving 332 cases, with an average frequency of 74% (12) (13) (14) .
In the present study, we analyze promoter methylation and protein expression patterns of the p16 gene in 100 patients with primary head and neck squamous cell carcinomas that have not been previously treated by radiation and chemotherapy. The epigenetic alteration and protein expression data are then correlated with various clinical parameters in an attempt to determine the prognostic significance of the p16 gene in head and neck squamous cell carcinoma.
MATERIALS AND METHODS
A total of 100 consecutive untreated cases of head and neck squamous cell carcinoma were gathered from the paraffin block archives in the Department of Pathology at John L. McClellan Memorial Veterans' Hospital, spanning a period from 1993 to 1998. Criteria for tissue selection were as follows: (1) primary surgical resection with curative intent or firsttime biopsy for adjuvant therapy; (2) an established diagnosis of squamous cell carcinoma by histomorphology of upper aerodigestive tract (lip, oral cavity, pharynx, and larynx); (3) no prior history of head and neck squamous cell carcinoma; and (4) no prior history of chemotherapy or radiation therapy. The histology of each case was reviewed, and representative tissue sections containing invasive squamous cell carcinoma were selected for immunohistochemical staining and extraction of DNA for promoter methylation analysis. Clinical follow-up was available for all patients until May 2002. Pertinent patient information was retrieved from the Computerized Patient Record System of the Department of Veterans Affairs.
Immunohistochemical Staining for the p16 Protein
Immunohistochemical staining was performed as described elsewhere (15) , except that the primary antibody was incubated at the dilution of 1:50 for 1.5 hours at room temperature, using a monoclonal antibody against the p16 protein (Ab-4, clone 16P04 or JC2; NeoMarkers, Fremont, CA). The p16 immunohistochemical staining results were interpreted semiquantitatively as follows: negative, Two pathologists (CLZ and CYF) evaluated the slides independently without prior knowledge of the methylation-specific PCR results. Any discrepancy in the immunohistochemical staining interpretation was resolved by reexamination of the cases by both pathologists. One head and neck squamous cell carcinoma case that showed unequivocal positive reaction in both nucleus and cytoplasm was used as the positive control and was included every time when immunohistochemical staining was performed.
Sample Collection and DNA Extraction
DNA samples were collected using the EX-WAX DNA Extraction Kit (Intergen Co., New York, NY) from five deparaffinized, 5-m-thick tissue sections from each tissue block. Human placental DNA (Sigma) was used as a negative control, and CpGenome universal methylated human DNA (Intergen Co.) served as a positive control, in which all CpG sites within the genomic DNA are chemically methylated.
Bisulfite Modification of DNA for MethylationSpecific PCR
In DNA samples from head and neck squamous cell carcinoma cases, negative and positive controls were subjected to bisulfite modification before MSP using CpGenome DNA modification Kit (Intergen Co.).
PCR Amplification and Primers
Amplification of the promoter region of the p16 gene was carried out in a Touchgene Gradient Thermal Cycler (Techne Inc., Princeton, NJ) in a 50-L PCR reaction mixture containing 2 L of bisulfite-treated genomic DNA, dNTPs (each at 200 M), primers (50 pmol each per reaction), 2.5 mM MgCl 2 , and 1.25 U Hotstar Taq (Qiagen, Valencia, CA) in 1ϫ PCR buffer. All reagents were supplied with the Qiagen Hotstar Taq Kit (Qiagen). The only exception was the dNTP mix (Roche Molecular Biochemicals, Indianapolis, IN).
Primers for the p16 gene were designed as follows: 5'-TTA TTA GAG GGT GGG GTG GAT TGT-3' (sense) and 5'-CAA CCC CAA ACC ACA ACC ATA A-3' (antisense) for the unmethylated reactions; and 5'-TTA TTA GAG GGT GGG GCG GAT CGC-3' (sense) and 5'-GAC CCC CGA ACC GCG ACCG TAA-3' (antisense) for the methylated reactions, as described elsewhere (16, 17) . Both primers are purchased from Operon Technologies Inc. (Alameda, CA). The PCR conditions were as follows: initial denaturation and hot start at 95°C for 15 minutes, then 40 cycles consisting of 30 seconds at 95°C, 30 seconds at 60°C (unmethylated reactions) or 65°C (methylated reactions), and 1 minute at 72°C, followed by a final 5-minute extension at 72°C. Positive and negative control DNA samples and controls without DNA were used for each set of PCRs.
Statistical Analysis
Statistical analysis was performed on the entire patient population as well as among different subpopulations. Survival was measured in months from the date of diagnosis to the date of death or to the date of last follow-up. Disease-free survival was the period of time from the initial diagnosis of tumor to the first time of tumor recurrence or the development of second primary cancer of the upper aerodigestive tract. Cause-specific survival was based on death as a direct result of tumor progression as compared with death due to other causes. Overall survival was defined as total death of all causes. The association among various factors, such as p16 promoter methylation, p16 protein expression, and clinical and pathologic parameters was analyzed with a cross-table 2 test. Survival functions and survival possibility of various prognostic factors were calculated with the KaplanMeier method, and the log-rank test was used to compare difference of survival curve between groups. The prognostic covariates analyzed included sex, age, tumor site, tumor size, nodal status, clinical stage, and presence or absence of chemo/radiation therapies. All P values were twosided. SPSS software (Version 11.0, SPSS Inc., Chicago, IL) was used for all statistical computation.
RESULTS
Of 100 patients, 91 underwent curative surgical resection, and 9, chemoradiation therapies as primary treatment for their tumors. The 91 surgically resected tumors all demonstrated clean margins by pathologic examination. All tumor tissues used in the study were derived from primary tumors without prior radiochemotherapy. Nine patients developed second primary tumors of the upper aerodigestive tract (8 lung and 1 esophageal carcinoma), 38 patients developed local recurrences, and 40 had regional lymph node metastasis. Among 100 patients studied, 69 died, 49 from their head and neck cancer and 20 from other causes. The patient pop- Table 1 .
Among 100 cases of head and neck squamous cell carcinoma analyzed for the p16 promoter methylation by methylation-specific PCR, aberrant p16 promoter hypermethylation was seen in 27 (27%) cases, with the remaining 73 cases (73%) showing no evidence of promoter methylation. Positive and negative controls worked appropriately in each round of PCR reaction. Representative p16 methylationspecific PCR was illustrated in Figure 1 .
Protein expression of the p16 gene was analyzed by immunohistochemical staining in all 100 cases. Fifty-four, 15, and 5 cases, respectively were determined to be negative (Ϫ), mostly negative (Ϯ), and weakly positive (ϩ) for the p16 protein, whereas 5 and 21 cases showed moderate (ϩϩ) to strong (ϩϩϩ) reactivity for the protein (see Materials and Methods for criteria). Thus, it appears that there are 74 cases (74%) that show apparent loss of p16 protein expression (negative to weakly positive by immunohistochemical staining) and 26 cases (26%) with high levels of protein expression (moderately to strongly positive by immunohistochemical staining). Representative p16 immunohistochemical staining was displayed in Figure 2 . Because promoter hypermethylation has been postulated as an important mechanism of gene silencing, correlation of p16 promoter hypermethylation with its protein expression was attempted. Among 27 cases that showed p16 promoter methylation, p16 protein expression was absent in 23 (85%) cases but present in 4 (15%) cases. Among 26 cases that displayed high levels of p16 expression by immunohistochemical staining, p16 promoter methylation was absent in 22 (85%) cases but present in 4 (15%) cases. Fifty-one cases displayed apparent loss of p16 protein (negative to weakly positive by immunohistochemical staining), yet absence of p16 promoter methylation. Overall, the p16 promoter hypermethylation was not significantly correlated with p16 protein expression levels (P ϭ .5).
The association of molecular, clinical, and treatment characteristics with 2-year disease-free survival was analyzed for the entire patient population (100 patients). The 2-year cutoff was used because Ͼ90% of head and neck squamous cell carcinoma recurrences occur within 2 years of initial curative treatment. Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression was correlated significantly with 2-year disease-free survival. Tumors arising in the lip were significantly correlated with increased disease-free survival as compared with tumors from other sites (P ϭ .002), probably because of early detection by selfinspection and early treatment. Factors that demonstrated significant association with decreased disease-free survival were increased tumor size (P Ͻ .0001), nodal metastasis (P Ͻ .0001), more advanced clinical stage (P Ͻ .0001), history of chemotherapy (P Ͻ .0001), and radiation therapy (p Ͻ .0001).
The association of 5-year cause-specific survival (i.e., patients who did not die of their disease) with molecular, clinical, and treatment characteristics was examined on the entire patient population (100 patients). Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression was correlated significantly with 5-year cause-specific survival. Patients whose tumor arose from the lip and who did not drink experienced increased cause-specific survival (P ϭ .002 and 0.04, respectively). Variables demonstrating significant association with decreased cause-specific survival included increased tumor size (P ϭ .001), nodal metastasis (P ϭ .006), more advanced clinical stage (P ϭ .002), history of chemotherapy (P ϭ .03), and radiation therapy (P ϭ .001).
The correlation of overall survival (i.e., patients who did not die) with molecular, clinical, and treatment characteristics of the entire patient population (100 patients) was also performed. Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression was correlated significantly with overall survival. Potential prognostic factors demonstrating significant association with decreased overall survival included increased tumor size (P ϭ .003), nodal metastasis (P ϭ .02), and more advanced clinical stage (P ϭ .005).
When overall survival was investigated more specifically in different subpopulations by alternatively censoring various tumor, nodal, and clinical stages (Table 2) , decreased overall survival was found to be significantly correlated with apparent loss of p16 protein expression in tumors at early stage, as characterized by T 1 (P ϭ .008), N 0 (P ϭ .05), and clinical Stage I (P ϭ .008) diseases (Table 2) .
Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression was correlated significantly with disease-free and cause-specific survival when tumors of early and advanced stages were separately analyzed.
We also determined whether p16 promoter hypermethylation or protein expression levels in the tumors of 100 patients correlated with various clinical, pathologic, and treatment parameters by 2 test. The presence of p16 promoter hypermethylation or protein expression levels in the primary tumor was not significantly correlated with age Ն65 years, tumor site, nodal status, and chemoradiation therapy. Apparent loss of p16 protein expression was significantly correlated with history of use of tobacco (P ϭ .05) and alcohol (P ϭ .005).
DISCUSSION
In this study, p16 promoter methylation and protein expression analyses were performed in 100 primary head and neck squamous cell carcinoma to determine whether p16 promoter hypermethylation or apparent loss of protein expression could affect other potential prognostic factors, tumor recurrence (disease-free survival), or overall patient survival. Our results indicated that history of to- bacco and alcohol use was significantly correlated with apparent loss of p16 protein.
Because tobacco and alcohol are two wellestablished and significant risk factors in the development of upper aerodigestive tract cancer, and inactivation of p16 tumor suppressor gene is frequently detected in upper aerodigestive tract cancer, several studies have attempted to establish a link between tobacco use and p16 promoter methylation in lung cancer and normal or preinvasive bronchial lesions from smokers (18 -20) .
The prevalence of p16 promoter hypermethylation was significantly associated with tobacco exposure in lung (20) and head and neck squamous cell carcinoma (21) . In animal studies, smoking increased the frequency of p16 promoter methylation in a dose-dependent pattern (22, 23) .
Although our analysis detected significant association of tobacco smoke and alcohol exposure with apparent loss of p16 protein, we failed to establish a similar correlation of p16 promoter hypermethylation with tobacco exposure in head and neck squamous cell carcinoma as demonstrated in lung cancer (20, 23) . Such a discrepancy may reflect a different mechanism involved in p16 inactivation between these two types of tobacco-related tumors. In head and neck squamous cell carcinoma, the p16 gene is inactivated by an epigenetic mechanism associated with promoter hypermethylation in Ͻ30% of the cases and by genetic factors, such as deletion and mutation in Ͼ60% of the cases (3, 24) . By contrast, in lung cancer, p16 inactivation is caused by promoter hypermethylation in Ͼ70% of the cases and by gene deletion or mutation in Ͻ30% of the cases (24) .
There appears an excellent agreement between p16 promoter methylation and loss of p16 protein expression in this study. Twenty-three of 27 (85%) cases with p16 promoter hypermethylation showed apparent loss of p16 protein expression, and 22 of 26 (85%) cases with high levels of p16 protein were free of p16 promoter methylation. The lack of overall correlation between p16 promoter methylation and protein expression could be attributed to a large number of cases (51%) in which apparent loss of p16 protein expression was not accompanied by the presence of p16 promoter methylation. Loss of p16 protein expression in these cases may result from aberrant genetic changes, such as homogenous deletion or inactivating mutations, commonly detected in head and neck squamous cell carcinoma (3, 24) .
In four cases, tumor cells displayed high levels of p16 protein expression, yet demonstrated p16 promoter hypermethylation (see Results). Such lack of correlation may be due to the heterogeneous p16 immunohistochemical staining patterns in primary head and neck squamous cell carcinoma. In fact, approximately 10% of the tumor cells in all four cases did not express the p16 protein, and this small population of negative cells could very well be the source of methylated DNA detected in these four cases. In future studies, areas with or without p16 protein expression in a given tumor could be separately microdissected using a laser-capture microdissection approach, and DNA samples from these two different areas would then be analyzed for promoter methylation.
Patients who received adjuvant chemoradiation therapy experienced a significantly higher tumor recurrence rate and shorter survival, and this most likely results from the tendency to apply adjuvant therapies to patients with advanced disease. Similar results were obtained in another study involving 91 primary head and neck squamous cell carcinoma (25) .
The correlation of p16 inactivation or aberrant genetic or epigenetic changes of the p16 gene with patient survival has been previously investigated in head and neck squamous cell carcinoma (14, 26 -28) , with no general consensus. In these studies, p16 alterations have been shown to be associated with decreased patient survival in two studies (14, 28) but demonstrate no difference in patient survival in two other studies (26, 27) , underscoring the complex relationship between p16 alterations and prognostic parameters, such as tumor recurrence or patient survival.
In the present study, we investigated how specific molecular markers (p16 promoter methylation or loss of p16 protein expression) affected diseasefree, cause-specific, and overall survival in 100 consecutive, untreated cases of head and neck squamous cell carcinoma. With the entire patient population as the basis for statistical analysis, tumor, nodal, and clinical stage remain the strongest prognostic predictors (see Results). Neither p16 promoter methylation nor loss of p16 protein expression can independently predict tumor recurrence and patient survival. However, when a subgroup of patients was analyzed by alternatively censoring tumor, nodal, and clinical stages, apparent loss of p16 protein expression (negative to weakly positive by immunohistochemical staining) was found to be significantly correlated with shortened overall survival in tumors at an early progression stage (T 1 , N 0 , and clinical Stage I tumors; Table  2 ). In this group of patients, the overall probability of surviving 5 years is about 80% in p16-positive tumors and 40% in p16-negative tumors (Table 2) . By contrast, in patients with tumors at more advanced stages (T [2] [3] [4] , N 1-2 , and clinical Stage II-IV tumors), the overall probability of surviving 5 years is similar between p16-positive and p16-negative cases, ranging from 25 to 35% (Table 2) .
Because p16 alterations occur early during tumor progression, it is not surprising to find that p16 inactivation primarily influences the patient prognosis in tumors at early progression stage. Similar results were obtained in lung cancer in which p16 promoter methylation was significantly associated only with Stage I tumor but not with tumors of more advanced stages (20) . Presumably, with tumors progressing to more advanced stages, additional alterations in other genes critical in tumor progression or invasion accumulate.
In summary, we detected p16 promoter hypermethylation and apparent loss of p16 protein expression in 27% and 74% of head and neck squamous cell carcinoma, respectively. When patient follow-up data were correlated with various clinical and molecular parameters, tumor size, nodal and clinical stage were the strongest prognostic predictors for disease-free survival (tumor recurrence), cause-specific, and overall survival in patients with head and neck squamous cell carcinoma. Even though apparent loss of p16 protein expression may be used to predict overall patient survival at earlystage head and neck squamous cell carcinoma, neither p16 promoter hypermethylation nor apparent loss of p16 protein expression can be used as an independent prognostic factor.
Exposure to tobacco and alcohol enhances the likelihood of p16 inactivation in head and neck squamous cell carcinoma, implying a link between p16 inactivation, the earliest detectable molecular event in the tumor development, and two wellestablished risk factors in head and neck squamous cell carcinoma.
